Compare GFAI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | CMMB |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Singapore | Israel |
| Employees | 1698 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.2M |
| IPO Year | N/A | 2023 |
| Metric | GFAI | CMMB |
|---|---|---|
| Price | $0.46 | $1.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 197.6K | 44.3K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | ★ N/A | $41.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.87 |
| 52 Week High | $1.50 | $3.86 |
| Indicator | GFAI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 50.77 |
| Support Level | $0.39 | $1.44 |
| Resistance Level | $0.70 | $1.86 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 52.57 | 60.26 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.